Crypto Updates

Vertex Pharmaceuticals’s Options Frenzy: What You Need to Know

Veteran Trader Peter Brandt Asks Macro Guru If Bitcoin Bull Has Finally Awoken From Deep Slumber

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals.

Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 15 trades.

If we consider the specifics of each trade, it is accurate to state that 26% of the investors opened trades with bullish expectations and 46% with bearish.

From the overall spotted trades, 6 are puts, for a total amount of $334,455 and 9, calls, for a total amount of $522,634.

What’s The Price Target?

After evaluating the trading volumes and Open Interest, it’s evident that the major market movers are focusing on a price band between $350.0 and $500.0 for Vertex Pharmaceuticals, spanning the last three months.

Volume & Open Interest Trends

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Vertex Pharmaceuticals’s options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Vertex Pharmaceuticals’s substantial trades, within a strike price spectrum from $350.0 to $500.0 over the preceding 30 days.

Vertex Pharmaceuticals 30-Day Option Volume & Interest Snapshot

Significant Options Trades Detected:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
VRTX CALL SWEEP BULLISH 06/21/24 $80.9 $75.0 $79.0 $360.00 $134.3K 212 20
VRTX CALL TRADE BEARISH 06/14/24 $68.5 $61.9 $64.5 $375.00 $129.0K 0 20
VRTX PUT SWEEP BEARISH 06/21/24 $6.3 $5.9 $6.2 $430.00 $114.5K 103 199
VRTX PUT SWEEP BEARISH 06/21/24 $6.5 $6.4 $6.4 $430.00 $96.6K 103 385
VRTX CALL SWEEP BULLISH 06/21/24 $10.0 $9.7 $10.0 $440.00 $48.0K 434 77

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid…

Click Here to Read the Full Original Article at Cryptocurrencies Feed…